First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 Inhibitor, LY3200882 in Patients with Advanced Cancer
Articolo
Data di Pubblicazione:
2021
Abstract:
A novel, selective, next-generation transforming growth factor-beta receptor type 1 small molecule inhibitor, LY3200882, demonstrated promising preclinical data. This first-in-human trial evaluated safety, tolerability, recommended phase 2 dose (RP2D), pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of LY3200882 as monotherapy or with other anticancer agents in patients with advanced cancer.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Yap, Timothy A; Vieito, María; Baldini, Capucine; Sepúlveda-Sánchez, Juan Manuel; Kondo, Shunsuke; Simonelli, Matteo; Cosman, Rasha; van der Westhuizen, Andre; Atkinson, Victoria; Carpentier, Antoine F; Löhr, Mario; Redman, Rebecca; Mason, Warren; Cervantes, Andres; Le Rhun, Emilie; Ochsenreither, Sebastian; Warren, Louise; Zhao, Yumin; Callies, Sophie; Estrem, Shawn T; Man, Michael; Gandhi, Leena; Avsar, Emin; Melisi, Davide
Link alla scheda completa:
Pubblicato in: